bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

Incorporating genetic selection into individual-based
models (IBMs) of malaria and other infectious diseases
Ian M. Hastings* and Raman Sharma
Liverpool School of Tropical medicine
Liverpool L35QA
United Kingdom

Ian.Hastings@lstmed.ac.uk
Raman.Sharma@lstmed.ac.uk

*corresponding author

1

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

Abstract.
Optimal control strategies for human infections are often investigated by computational approaches
using individual-based models (IBMs). These typically track humans and evaluate the impact of
control interventions in terms of human deaths, clinical cases averted, interruption of transmission
etc. Genetic selection can be incorporated into these IBMs and used to track the spread of
mutations whose origin and spread are often driven by the intervention, and which subsequently
undermine the control strategy; for example, mutations which encode antimicrobial drug resistance
or diagnosis- or vaccine-escape phenotypes. Basic population genetic descriptions of selection are
based on infinite population sizes (so that chance fluctuations in allele frequency are absent) but
IBMs track finite population sizes. We describe how the finite sizes of IBMs affect simulating the
dynamics of genetic selection and how best to incorporate genetic selection into these models. We
use the OpenMalaria IBM of malaria as an example, but the same principles apply to IBMs of other
diseases. We identify four strategies to incorporate selection into IBMs and make the following four
recommendations. Firstly, calculate and report the selection coefficients, s, of the advantageous
allele as the key genetic parameter. Secondly, use these values of â€˜sâ€™ to calculate the wait-time until
a mutation successful establishes itself in the population. The wait time for the mutation can be
added to speed of selection, s, to calculate when the mutation will reach significant, operationally
important levels. Thirdly, quantify the ability of the IBM to robustly estimate small selection
coefficients. Fourthly, optimise computational efficacy: when â€˜sâ€™ is small it is plausible that fewer
replicates of larger IBMs will be more efficient than a larger number of replicates of smaller size.

2

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

1. Introduction.
Advances in computational power over the last 20 years have allowed sophisticated, individualbased models (IBMs) of infectious diseases to be developed and applied to important human and
animal disease. These are particularly valuable in diseases with complex transmission through vector
species and/or complex clinical aetiology because they allow considerably more realism to be added
to the fundamental susceptible-infected-recovered (SIR) models which are usually the first analyses
used to investigate disease epidemiology. The next challenge for these IBMs is to incorporate
genetic selection into the disease epidemiology. Most pathogens readily evolve in response to
human interventions. For example, drug resistance almost inevitably evolves in response to drug
deployment, and mutations arise that change the antigenic profile of the molecules detected by
molecular diagnosis, making the pathogens invisible to diagnosis. Incorporating this evolution into
IBMs is not straightforward and this manuscript discusses how it may best be achieved in terms of
accurately quantifying the selection process in a computationally efficient manner.
Our expertise lies in malaria and IBMs of malaria have been recently, and comprehensively,
reviewed by Smith and colleagues [1]. The development of several IBM models was supported by
the Bill and Melinda Gates Foundations and the resulting consensus exercises co-ordinated by these
groups has been influential in evaluating the potential impact of intervention such as partiallyeffective vaccines [2], mass drug administration (MDA) programmes [3], and the impact of new
diagnostic tools [4]. These publications focused on the relatively short-term impact of interventions
but the historic problem with such interventions is that the malaria populations evolve and adapt to
the challenges posed by the interventions. The obvious examples are vaccine-based interventions
driving vaccine-insensitive variants (e.g. [5, 6] and discussion in [7]), drug-based interventions driving
drug resistance (e.g. Figure 3 of [8]), and deployment of rapid diagnostic test (RDTs) driving
mutations that prevent the infection being detected and diagnosed (such as hrp2- deletion mutants)
[9, 10]. The basic dynamics of spread of such mutations can be obtained from standard population
genetics methodology (e.g. [11-13] and later). However, the simplicity of these methodologies
means the analyses must focus on malaria genetics and often largely ignore the epidemiological and
clinical frameworks within which these selection processes operate. Consequently, there is
increasing interest in incorporating genetic selection into the IBMs of malaria. The use of IBM makes
the selective background far more realistic and can incorporate factors such as heterogeneity in
mosquito biting, the effectiveness of diagnosis, the effect of human acquired immunity, the impact
of super-infection, local patterns of clinical treatment, amongst other factors.
There is a considerable amount of population genetic theory that many epidemiological modellers
may be unaware of, presumably through their background as mathematicians and/or computer
scientists. Population genetic theory developed over the last 100 years largely in the absence of
computer infrastructure so there is a large amount of basic theory that can be combined with largescale IBMs of disease transmission to make selection more transparent, more computationally
efficient and, importantly, to make the results and outputs comparable across simulation platforms.
The aim of this paper is to describe how this may be achieved. The significant differences between
the two approaches is that simple populations genetic theory usually assumes infinite population
sizes (so that random fluctuations in allele frequency are absent) whereas IBMs track finite
population sizes. There are two related effects that occur in finite populations that affect how we
bring genetic selection into IBMs and these need to be understood before we describe the
integration of population genetics into IBMs. Both effects arise because IBMs track numbers, rather
than frequencies, of each genotype of parasites:

3

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

Stochastic fluctuation may result in â€œgenetic extinctionâ€ when small numbers of one allele
type are present. This effect emphasises the difference between the expected change in the
number of infections carrying the allele, and the actual change. Suppose there are 10
infections carrying the advantageous allele (e.g. drug resistance) in the IBM and the
selection coefficient (see later) acting on the allele is 0.05, i.e. the allele frequency is
expected to increase by 5% per malaria generation which is roughly in line with field
estimates (see later). The expected number of resistant infections next generation is
10*1.05= 10.5 but it is obviously impossible to leave exactly 10.5 infections: the number of
resistant infections must come from a distribution i.e. 0,1,2,3,4,5, and variation in numbers
of transmission is typically large. Importantly, there is a small, but finite, probability of
leaving zero infections next generation; in the case â€œgenetic extinctionâ€ has occurred i.e. the
allele has been lost from the populations. The risk of genetic extinction is greatest when
there are small number of one type of allele. This is most notable for new mutations, which
are by definition, present at a single copy when they first arise; in that case, even with a
selective advantage of 5% then the mutation will be lost by chance between 90% and 99% of
the time depending on the level of heterogeneity in transmission (see discussion in Box 2 of
[14]). Hence it is highly desirable to avoid low numbers of infections with any allelic type in
the IBM as they may go genetically extinct purely by chance, even if that allele is
advantageous over the longer term.

Genetic drift is similar to stochastic change described above but occurs at higher numbers.
The risk of random genetic extinction has largely passed when there are large numbers of
the advantageous allele, but random fluctuations may obscure the underlying selection.
Suppose there are 1,000 resistant infections with selective advantage of 5% then on average
there will be 1000*1.05= 1,050 next generation. But the stochastic variation described
above will still occur and cause chance variation around this expected number. This is
termed genetic drift and introduces â€˜noiseâ€™ that causes variation in the spread of the
advantageous allele. A critical point is that at low selection coefficients the drift can
completely obscure the dynamics of spread: in effect the â€˜signalâ€™ (selection pressure
favouring the alleles) is lost in the â€˜noiseâ€™ (genetic drift). Intuitively, and correctly, the effects
of drift become more pronounced at small population sizes i.e. the smaller the number of
infections tracked in the IBM, the larger the impact of drift. This is a well-knows
phenomenon in population genetics which, for our purposes, sets a limit on the sensitivity of
the IBMs to track selection. i.e. for any given size of IBM there comes a point when selection
coefficient become so small that it is obscured by drift and the IBM can no longer effectively
track the genetics. The impact of this effect is discussed in detail later in section 2.3

A final key genetic concept is that of effective population size, Ne, and the â€œcensusâ€ population size,
N. The latter is simply the number of all malaria clones in the population (i.e. of all allelic types)
which we will take as the number of infected humans present in the IBMs (ignoring, for convenience,
the fact that some infections may be superinfections i.e. consist of several clones). Population
genetic theory used to investigate finite population sizes has been developed for idealised, paradigm
population that are assumed to have a constant census size N and whose members are assumed to
have equal reproductive potential. Most real populations, including most infectious disease species,
do not fit this paradigm, which led to the concept of an effective population size which is the size of
the paradigm population that would have equivalent properties of that of the census size N (see [15]
4

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

for an introduction to N, Ne and its impact on genetic drift). Importantly, Ne in natural populations is
invariably much smaller than N. Notably there is considerable heterogeneity in the reproductive
success of many infections depending on host factors such as the level of host immunity, the
number of secondary contacts made by that person (if the disease is directly transmitted) or how
often that person is bitten (if the infection is indirectly transmitted by disease vectors such as ticks or
mosquitoes). Ne also falls as pathogen populations â€œbottleneckâ€ due to seasonal patterns of
transmission (a common phenomenon associated with mosquito-transmitted disease) and largescale control programmes (such as bed net distribution programs to control malaria) may cause
significant reductions in pathogen census population sizes. These factors will substantially reduce Ne
with important consequences for genetic drift which, as we show later, limits the sensitivity of IBMs
to track selection of advantageous alleles with low selection coefficients. The important point is that
the number of infections being tracked, N, may appear high, but Ne may be considerably lower
which has a large impact on the IBMsâ€™ ability to quantify the spread of advantageous mutations
The purpose of this manuscript is to describe how these effects of finite population sizes need to be
clearly recognised when incorporating genetic selection into IBMs and describe and discuss how
their impact may be mitigated.

2. Methods and results
We use the individual-based malaria simulation package OpenMalaria to simulate the spread of drug
resistance. This is a highly sophisticated IBM of malaria transmission that incorporates factors such
as the acquisition of human immunity against malaria infection, local treatment practices, the level
of mosquito transmission, and has been widely used to investigate many aspects of malaria
transmission and control. The consequence of this sophistication is that it is highly computationally
intensive, so makes an ideal test platform to develop computationally efficient methods of
incorporating genetic selection. Technical details of how we ran OpenMalaria are given in
Supplementary Information but, in summary, we run the simulation over a 10 year burn-in period
before introducing the advantageous allele. OpenMalaria outputs the number of inoculations of
each allelic type every 5 days as a cumulative total over that period. We extract the proportion of
inoculations carrying the advantageous allele from each 5-day time point to monitor the spread of
the advantageous allele and it is these data that enter the regression to estimate the selection
coefficient. The number of humans to be tracked in OM is user-specified (we track 10,000
otherwise indicated) and we can vary the user-defined entomological inoculation rate (EIR; the
mean number of infective bites per human per year) to vary the prevalence of malaria infection; by
default we simulate a prevalence of 15% averaged over all ages based on diagnosis by microscopy.
In these simulations we assume the â€œadvantageous alleleâ€ is one encoding drug resistance; the same
principle applies to all advantageous alleles, but alleles encoding drug resistance allow us to easily
alter their selective advantage simply by altering their level of resistance to the drug being deployed.
In the following examples, the drug is assumed to be dihydroartemisinin+piperaquine (DHA+PPQ)
which is a widely used front-line antimalarial drug. We simulate different selection intensities driving
the advantageous allele by varying the resistance level (IC50) to PPQ; increasing the IC50 value
encoded by the advantageous allele increases the level of drug resistance and hence defines more
highly advantageous mutations (Table 1). This strategy allows us to investigate the range of selection
coefficients that covers â€œtypicalâ€ values for drug resistance selection which has been estimated at
~0.02 to ~0.12 (see later discussion). Results obtained for IC50 shifts of 1.1x and 1.4x IC50 fold are

5

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

used as illustrative examples (except in part 2.3) as they represent selection coefficients of ~0.02
and ~0.06 respectively using our default prevalence of 15%. Values higher than this gave largely
predictable, deterministic results and IC50 shifts in between these values of 1.1x and 1.4x were found
to behave in an intermediate fashion that therefore added little to the overall picture.

(2.1) Methods used to measure and report the dynamics of spread.

Figure 1A shows the spread of an advantageous allele in a haploid organism. Most selection
processes start from low frequency so most of the timescale taken to reach operationally significant
frequencies occurs at low frequencies. Tracking the entire selection period is both computationally
intensive and will also suffer from stochastic fluctuations in low allele number as described above.
Fortunately, bacteria and malaria are haploid (we know of no selection that occurs in malariaâ€™s brief
diploid phase in mosquito oocysts) so dominance between the two alleles is not an issue and the
spread can be linearised as shown on Figure 1B. This offers an methodological alternative to
measuring spread over long duration at low frequency: it suggests that, providing selection pressure
does not alter as a consequence of allele frequency (an important assumption, discussed later) that
spread can be measured over a short period of time (computationally convenient), quantified at
relatively high frequencies (minimising the impact of stochastic changes in allele frequency), and
extrapolated to the whole selection process.
We argue that this extrapolation is best achieved by estimating the selection coefficient, usually
denoted â€˜sâ€™, to quantify the rate of spread. This parameter describes the relative â€˜fitnessâ€™ of the
mutant as 1+s compared to the fitness of the wildtype which has fitness 1.0 and is conventionally
reported in units of a single malaria generation (see below). Hence, at low frequencies, the mutant
spreads at a rate s per generation (so if s=0.05, then it increases by 5% per generation). Selection
coefficient can be easily measured independently of allele frequency, as the slope of ln[p/(1-p)] over
time where p is the frequency of the advantageous allele (Figure 1B). Computer simulation generally
run in â€œrealâ€ time, usually one-day timesteps, so we need to convert the slope of ln[p/(1-p)] from
real time to generations. In the current example, this requires an estimate of the duration of a
malaria generation. In previous work we have assumed 5 generations per year [16] although other
authors used different values, for example Anderson and Roper [17] assumed 6 generations per
year. Here we will assume 6 generations per year meaning that each generation lasts 365/6â‰ˆ60 days
so the slope of ln[p/(1-p)] estimated on a timescale of days need to be multiplied by 60 to obtain the
selection coefficient. Finally, note that s can be negative if the allele is actively being removed from
the population (for example by natural selection if the allele is no longer being selected and has a
fitness cost) or if the allele frequency decreases due to chance fluctuations (genetic drift); the
principles described above apply equally to this situation i.e. its magnitude is measured as ln[p/(1p)] over time but it will have a negative value (see, for example, Figure 3 of Anderson and Roper
[17]).

The dynamics shown on Figure 1 are those predicted by elementary population genetic theory i.e.
constant selection pressure in an idealised population of infinite size. Individual-based simulations
do not fit this paradigm as selection coefficients may vary over time, most plausibly as a function of
allele frequency (see later discussion), and IBMs, by definition, do not track infinitely large
6

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

populations. All IBMs that we are aware of require a â€œburn-inâ€ period to allow malaria epidemiology
to stabilise in the presence of the human â€œinterventionâ€ (e.g. drug-, RDT-, or vaccine-deployment)
prior to introducing the advantageous allele and tracking its spread. This â€œburn inâ€ period forces
researchers to make three key decisions when estimating selection coefficients after introduction of
the advantageous allele i.e. what should be the starting frequency of the advantageous allele when
introduced into the IBM, when should measurement of ln[p(1-p] start, and how long should
measurement last? We illustrate the trade-offs inherent in making these decisions.
Each OpenMalaria simulation was run 100 times for each resistance level with different random
number seeds to check consistency of estimates over â€˜identicalâ€™ runs. Selection coefficients were
obtained by linear regression of ln[p/(1-p)] as described above. We set frequency boundaries to
avoid the regression tracking small numbers of alleles which would occur at high or low frequencies.
The reasoning is that outside these boundaries there may be a relatively small number of alleles of
one type and stochastic variation in their number may obscure the deterministic change in their
frequency; i.e. the effect of genetic drift as described above. The upper boundary was an
advantageous allele frequency (AAF) >90% in all simulations. The lower boundary depended on
initial AAF: it was AAF<30% if initial AAF frequency was 50%, AAF<1% if initial AAF was 10% and
AAF<0.1% If initial AAF was 5% or 1%; note that the latter two initial AAF values were only every
used to produce the data shown on Figure 2. The regression was terminated if the advantageous
allele frequency fell outside these boundaries and regression only used data between the initial AAF
frequency and the point at which AAF first fell outside the boundaries.
(i) Decision #1: What is the appropriate starting allele frequency in the simulation?
Most advantageous alleles start at very low frequencies and most of the timescale of spread occurs
at very low frequencies before its clinical impact becomes apparent (the period of complacency [18])
as shown on Figure 1A. Ideally, we would investigate spread at low frequencies, but it is generally
extremely difficult to track these very low frequencies in individual-based simulations because of the
effect of stochastic variation described above. A biologically reasonable starting frequency might be
10-5 meaning 1 in 100,000 infections have the advantageous allele but this is obviously impossible if
the simulation, for example, has only 10,000 infected individuals. Even if the simulation did track
100,000 infected individuals, it would still be problematic to introduce an allele at a frequency of 1 in
100,000 as the single infection would exhibit considerable stochastic variation in its subsequent
number of secondary, tertiary etc. infections for reasons described earlier i.e., for example, if s=0.1
then the infection cannot leave exactly 1.1 offspring but 1.1 will be an average of a distribution with
0,1,2,3,4â€¦ secondary infections. The key computational requirement is that small numbers of
resistant infections need to be avoided. So a decision needs to be made on starting frequency that
ensures a reasonable number of each type of allele such that stochastic variations due to genetic
drift are minimised (i.e. the dynamics are largely â€œdeterministicâ€ in the population genetic jargon).
The dynamics of Figure 1 assume constant selective advantage over time. This assumption may hold
at very low frequencies where small changes in frequency, say from 10-6 10-5, do not significant
affect malaria epidemiology. Once frequencies become larger, the epidemiology may begin to
change because of the presence of the advantageous allele; for example. spread of a hrp2-deletion
allele might allow malaria to resurge, treatment rates to fall, and prevalence to increase. We show
how selection coefficients may differ depending on epidemiology in Table 1 which shows the impact
of a large, but illustrative, 10-fold reduction in malaria prevalence. The selection coefficient is almost
10 times higher when malaria prevalence is 15% than when prevalence is 1.5%. The most likely
explanation is that the percentage of people with detectable drug level is 35% in the 15% prevalence
group falling to 8% in the 1.5% prevalence group. The proportion of people in the population with
7

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

sub-therapeutic drug levels is an important driver of resistance (see Box 1 of [19] and Box 2 of [20]
for discussions) so higher selection coefficients are generated when there are higher proportion of
patients with detectable drug levels. A ten-fold change in prevalence is obviously a very large
epidemiological change but serves to illustrate our point about the potential impact of changing
epidemiology on estimates of selection coefficient.
There are therefore two conflicting considerations in choice of initial advantageous allele frequency.
Ideally, it should be as low as possible to reflect the condition under which most selection occurs
(Figure 1) but this is weighed against the benefits of higher frequencies in reducing stochastic noise
in allele spread. We examined different values of starting frequencies as shown in Figure 2 and
values of 10% and 50% are also compared in Figures 3, 4 and SI Figure S3. We decided on 50% as the
default value to minimise stochastic change because Figure 2 shows it greatly reduces the variation
in estimating selection coefficient. Note, however, that when values of s are sufficiently high that
they reliably dominate genetic drift (s>~0.1 in our default simulations based on 10,000 humans with
15% malaria prevalence) then an initial frequency of 10% can be used; this allows regression to be
measured before advantageous allele frequency exceeds the 90% threshold applied in our analyses.
We discuss the implications of this choice of initial frequency later and recommend that researchers
explicitly discuss how their results obtained at high frequencies are likely to also apply to selection at
much lower frequencies.

(ii) Decision #2: How long after introduction of the advantageous allele should we start measuring
the slope of ln[p/(1-p)]?
Decision #1 means we have to introduce the advantageous allele at a relatively high frequency which
will inevitably change disease epidemiology, so the second decision is how long after the
introduction of the advantageous allele should we start to measure â€˜sâ€™? The best policy would be to
start measuring selection as soon as possible after its introduction to minimise the impact of any
epidemiological changes. Plausible start times could be immediately after introduction, after 20 days
(to allow secondary infections to be acquired by the mosquito, develop in the midgut, be inoculated
and become patent in humans), 60 days (the estimated malaria generation, see above), and so on.
We investigated this by varying the start time and quantifying its effect on estimated selection
coefficients. Example results using the default duration of ln[p/(1-p)] regression of 720 days are
shown on Figure 3 but the results were fairly consistent across other durations of regression (Figure
S1). Start times >60 days do not appear to bias the median estimate of â€˜sâ€™ nor does it make a big
difference to the coefficient of variation around the estimates. We therefore selected a delay of 60
days, equivalent to a single malaria generation, to allow transmission to stabilise.

(iii) Decision #3: How long should we regress the slope of ln[p/(1-p)]
The aim is to make the duration of regression sufficiently short that the epidemiology over that time
period has not changed significantly due to the introduction of the advantageous allele, while
ensuring that the duration is sufficiently long that accurate estimates of â€˜sâ€™ can be obtained from the
regression. We investigated this effect by altering the duration of regression and quantifying how it
affects the estimation of selection coefficients, see Figures 4 and lower panel of Figure S2, assuming,
as justified above, that the regression starts 60 days after introduction of the advantageous allele.
The duration does not appear to bias the mean or median estimate of â€˜sâ€™ but did affect the variation
in the estimates, the variation decreasing as duration increased (Figure S2), presumably because
8

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

more datapoints enter the regression. We chose 720 days as the duration of our regression as it
returns stable estimates of â€˜sâ€™ with relatively small coefficients of variation (Figure 4).
Finally, We needed to confirm that spread of the advantageous allele had no significant impact on
epidemiology (or, if it did, that it did not alter the magnitude of â€˜ sâ€™) so that the value of â€˜sâ€™ from our
regression will be a valid approximation for that occurring during the critical period of spread from
low initial frequencies. Figure S1 shows that the estimated selection coefficient did not
systematically change with time since introduction of the advantageous allele; frequency will have
increased over this time implying that estimates of selection coefficient were not affected by allele
frequency.

(iv) The impact of these decisions
There appear to be no objectively â€œcorrectâ€ solutions to these three decisions, all of which incur
trade-offs. It may be possible to tailor the decisions to specific circumstances. For example, if
selection coefficients are known to be large, and it is computationally feasible for the simulation to
track a large number of infections in a reasonable time frame, then the advantageous allele may be
introduced at a much lower starting frequency to minimise its epidemiological impact after its
introduction. We wished to avoid using different methods in different circumstances and wanted to
identify a robust method which we believe will be applicable over the wide ranges of parameter
spaces explored by OpenMalaria, hence we settled on the above methodology. We are not
prescriptive on the methodologies to be employed but herein describe what trade-offs we
encountered and how we addressed them; importantly, these will almost inevitably occur when
tracking genetic selection in IBMs of most infectious diseases. We used in OpenMalaria as a case
study in decision making which people using other IBM for other alleles, may find useful.
In summary, the default method we use for estimating â€˜sâ€™ in OpenMalaria is as follows. The
advantageous allele is introduced at 50% frequency (with the caveat that if â€˜sâ€™ is very high, starting
frequency of 10% gives a longer duration of regression before frequency exceeds our limits of 90%
which may improve accuracy). The regression then starts 60 days after the introduction of the
advantageous allele (this one-generation time lag allows malaria transmission stages, gametocytes,
to mature and reflect the preferential transmission of the advantageous allele) and continues over
720 days (2 years) which, assuming 6 generations per year (see below) is 12 malaria generations.
OpenMalaria outputs data every 5 days, so the full regression period of 720 days provides 144 data
points for the regression. We then run repeated simulations and check the boxplot of our estimates
(figure 2 to 4) or means and coefficients of variation (Figure S1 to S3) to confirm that we have
reasonably stable estimates of â€˜sâ€™.

(2.2) Incorporating mutations into the IBM
We argued that selection coefficients be measured when advantageous alleles are present at high
frequency (to minimize the impact of genetic drift) and used to extrapolate spread of the
advantageous allele over the whole period of selection. This period of selection can start from any
frequency, so a key question is what starting frequency is most appropriate for this extrapolation. In
some circumstances we may be able to simply assume that advantageous alleles are already present
at a given initial frequency, for example at a mutation/selection equilibrium. In these circumstances,
it is straightforward to use the estimate of â€˜sâ€™ to track their subsequent spread from their initial,
9

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

presumably very low, frequency. For example, if the initial advantageous allele frequency is p(0)
then the frequency after â€˜tâ€™ generations, p(t) can be obtained by substitution as in the following
equations. Figure 1B shows that

ln [

ğ‘(ğ‘¡)

] = ln [

1âˆ’ğ‘(ğ‘¡)

ğ‘(0)
1âˆ’ğ‘(0)

] + ğ‘ ğ‘¡

Or, equivalently,
ğ‘(ğ‘¡)
1âˆ’ğ‘(ğ‘¡)

=

ğ‘(0)
1âˆ’ğ‘(0)

ğ‘’ ğ‘ ğ‘¡

Equation 1

Noting that if the odds of p(t) are â€˜xâ€™, i.e. p(t)/[(1-p(t)]=x, then the allele frequency at â€˜tâ€™ is given by
p(t)=x/(1+x)].
Or, alternatively, the time taken to reach a frequency of p(t) from p(0) can be obtained by
substitution as

ğ‘¡=

ğ‘(ğ‘¡)
ğ‘(0)
]âˆ’ln [
]
1âˆ’ğ‘(ğ‘¡)
1âˆ’ğ‘(0)

ln[

ğ‘ 

Equation 2

Similarly, the selection coefficient can be obtained from field data reporting frequencies at different
times (a common form of data; see later) as

ğ‘ =

ln[

ğ‘(ğ‘¡)
ğ‘(0)
]âˆ’ln [
]
1âˆ’ğ‘(ğ‘¡)
1âˆ’ğ‘(0)

ğ‘¡

Equation 3

Alternately, the assumption may be that the advantageous alleles are not yet present in the malaria
population, in which case their de novo input by mutation must be incorporated into the IBM. The
problem then is to track the origin and spread of such mutations while avoiding having very low
numbers of the advantageous allele within the IBM. We suggest the following strategy to allow the
input of de novo mutations into the IBM as a 4-stage process.
(i) Define â€œmutation rateâ€, Î¼, as a user-defined input into the simulation We define this mutation
rate per inoculum, Î¼, which in our malaria IBM is the probability that a single mosquito bite delivers
an inoculum consisting solely of parasites containing the advantageous allele. This allows details of
how mutations arise to be studied external to the IBM as discussed later. Importantly, quantifying
the input of new mutations as Î¼ simplifies the introduction of mutations into IBMs, and reduces the
stochastic element of their input and improves comparability between replicate runs.
(ii) Use the selection coefficient obtained above to calculate the probability that the mutation
successfully survives chance extinction in the first few transmissions after its introduction. This is
discussed in more detail elsewhere [14] but the basic results is that if reproductive success follows a
Poisson distribution then the probability that the de novo mutation survives to become established
in the population is approximately 2s when s<~0.1 [21-23]. Reproductive success is generally not
Poisson and is much more over dispersed; if we quantify this overdispersal by a negative binominal
10

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

distribution, as is commonly used in infection transmission, then probability of establishment may
be reduced substantially (Table 1 of [14] and see Parsons el al [24] for a more sophisticated
discussion). We denote the probability of a novel mutation surviving chance extinction as Î¨ and can
estimate it as
Î¨=s

Equation 4

Based on Table 1 of [14] which shows this relationship holds for values of s from ~0.01 to~ 0.1 and a
negative binomial distribution of transmissions (a characteristic of most parasite infections) with a
dispersal parameter of 0.1 (moderately over-dispersed). Alternative estimates of Î¨ can be obtained
by simulation under different assumptions of dispersal parameter [14], but this simple relationship
serves its illustrative role here.

(iii) We can then calculate the expected number of new mutations per (malaria) generation, Î¸, as
Î¸=Î¼Î¨Î»

Equation 5

Where Î» is the number of successful transmissions in the IBM per mosquito generation. In
epidemiological terms this is known as the force of infection (FOI). This is typically much lower than
the infective contact rate because many contacts do not produce a viable infection due to factors
such as low inoculum size, acquired immunity in the human, etc. In vector-borne disease the contact
rate is usually quantified as the entomological inoculation rate (EIR) i.e. the average number of
infective bites per human per time period. In the specific case of malaria, Smith and colleagues [25]
established a relationship between EIR and FOI which, since malaria EIR is commonly estimated in
the field, enables IBMs of malaria to be calibrated against field data when attempting to incorporate
mutational input.

Equation 4 enables us to calculate the distribution of â€œwait timesâ€ until a mutation successfully
enters the population; rather counter-intuitively to some readers, this is an exponential decay,
rather than a normal distribution, see Figure 2 of [14] i.e.
ğ‘“(ğ‘¡) = Î¸ğ‘’ âˆ’Î¸t

Equation 6

Sampling from this distribution provides the time (in generations) until a mutation first successfully
enters the IBM.
(iv) Having obtained a wait time, we can then use â€˜sâ€™ to calculate its subsequent spread until it
reaches any given point e.g. time to reach 5% frequency. Assume, for example, that the IBM is
tracking a population of 1,500 infections (note it is number of infections, not number of humans)
then the initial frequency p(0) of a de novo mutant is 1/1,500. The distribution of times for a de novo
mutation to successfully enter the population and subsequently reach any given frequency p(t) can
be simply obtained by summing the wait time for its successful input into the population (sampled
from Equation 6) and the time for its subsequent spread to p(t) (Equation 2). The implicit assumption
in this calculation is that the rate of de novo mutations entering the population is small compared to
the selective advantage (i.e. Î¸ <<s), so that the spread of the first mutation dominates any later
input of new mutations, meaning that we need only track the spread of the first mutation. If this is
not the case, the calculation for spread can still be made but allowing recurrent, sporadic de novo
mutations to enter the population using Equation 5.

11

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

There are two clear advantages of this four-stage strategy of incorporating mutations. Firstly, it
allows biological details of how mutations occur to be removed from within the IBM which allows
better comparability between studies. Authors may differ in their underlying assumptions about
how mutations arise, so this strategy removes such differences from the simulations. Secondly, it
removes the temporal variation in wait-times for mutational input from the IBM and places it in
Equation 5. It is obviously easier and much faster to repeatedly sample from the distribution in
Equation 5 than to repeatedly run replicates of the IBM to capture and quantify this stochastic
variation in mutational input.

(2.3) Identify the power of the IBM to accurately estimate small selection coefficients
In Part 2.1, we deliberately focussed on selection of sufficient strength that selection was able to
dominate genetic drift in our simulations i.e. selective coefficients >2% and a malaria population
census size, N, of ~1,500 (i.e. 10,000 humans tracked with a malaria prevalence of 15%).
IBMs typically simulate humans. If disease prevalence is low as, by definition, occurs in nearelimination scenarios, then the pathogen population size may be small. Suppose a simulation of
10,000 humans with a pathogen prevalence of 1% gives a pathogen population size of 100. This may
seem large but, as described earlier, it is effective population size, Ne, that is important rather than
the observed or â€œcensusâ€ population size, N. The reason this is so important is that Ne sets the
sensitivity of the IBMs to detect selection acting on advantageous alleles. As Ne becomes small,
random frequency changes due to genetic drift become so large that they can obscure selection
processes. There are various approximations for deciding whether selection or drift will be the
dominant dynamics driving changes in allele frequency but, generally, drift dominates when s<<1/Ne
and selection dominates when s>>1/Ne, and both play important roles when s and 1/Ne are around
the same magnitude. Suppose selection coefficient is 0.02 which is moderately strong i.e. a 2%
increase per generation, this suggest it will only dominate drift when Ne>> 50.
The problem is that, except in very simple cases, there is no algebraic means of converting the
â€œcensusâ€ population size observed in IBMs, into the equivalent Ne. One option would be to track
neutral (i.e. non selected) genetic markers in the simulation and use the level of linkage
disequilibrium to estimate Ne (e.g. [26]). However, it is probably more informative to empirically
estimate the limit of sensitivity of the IBM to detect small selection coefficients. We demonstrate
this by further reducing the resistance level (IC50) of the advantageous alleles below that
investigated in Part 2.1 i.e. fold increases in IC50 are less than 1.1 (Table 1). The dynamics of spread
when selection coefficients are low is shown on Figure 5 and shows the coefficient of variation
around mean estimates of â€˜sâ€™ (cf Figures 3 and 4 where selection is higher and dominates drift).
Figure 5 has the following pattern:
The top line was obtained from the following simulation:
â€¢

10,000 patients with malaria prevalence of 15% and starting mutant frequency of 10%;
N=1,500

There are then two lines that are effectively superimposed i.e.
â€¢
â€¢

Increasing the starting advantageous allele frequency to 50%; this increase sensitivity
compared to the top line, presumably by reducing stochastic variation is allele number.
Increasing population size to 100,000 and decreasing malaria prevalence to 1.5%; this gives
the same malaria census population size as 10,000 people with 15% prevalence (i.e.
12

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

N=1,500) so it is an excellent demonstration that it is the malaria population size being
tracked not the human population size, that is the critical factor governing ability of the IBM
to estimate selection coefficients.
Finally, there is a lower line obtained from the following simulation as follows
â€¢

100,000 patients with malaria prevalence of 15% and starting mutant frequency of 50%. This
has N=15,000 i.e. a 10-fold greater malaria population size compared to the 100,000
population with 1.5% prevalence. As expected, the ability of the IBM to accurately estimate
selection coefficients is greatly increased.

As expected, the accuracy of estimation does increase as the number of infections tracked is
increased, either by increasing the number of patients tracked and/or by increasing malaria
prevalence (Figure 5). In the specific case of default simulations of 10,000 humans with 15% malaria
prevalence (blue line of Figure 5), they are unable to accurately estimate values of â€˜sâ€™ less than about
0.02 because the CV increases to the extent that a large number of replicates would be required to
get an accurate standard error around the estimated value of s. Increasing population size to
100,000 enables estimates of s down to around 0.005 (green line of Figure 5). We base this limit on a
CV<~1 but this is arbitrary and illustrative and, in reality, the limit depends on how many replicates
can be feasibly run. A larger number of runs will reduce standard error around the estimates but,
importantly, it may be more computationally efficient to run fewer, large simulations, rather than a
larger number of small simulations. Recall that standard error around the mean (SEM) is given by
ğ‘†ğ¸ğ‘€ =

ğœ
âˆšğ‘›

Where Ïƒ is the standard deviation of estimates and n is sample size. If we take the central point
plotted in Figure 5 (i.e. s=0.0156; see Table 1) with 50% starting frequency and 15% prevalence, then
a population size of 10,000 has a CV of 1.43 (figure 5) resulting in Ïƒ =0.022 and a population size of
100,000 has a CV of 0.27 (figure 5) resulting in Ïƒ =0.0042. Assuming the population simulation scales
(i.e. a run tracking 100,000 individual requires 10 times more run-time than a population of 10,000)
then a smaller number of simulations tracking a larger population provides better accuracy. For
example, 100 simulations of 10,000 individual gives SEM of 0.0022 while 10 runs of 100,000 gives a
SEM of 0.0013. Similarly, 50 runs of 10,000 gives a SEM of 0.0032, while 5 runs of 1000,000 gives a
SEM of 0.0018. It is therefore likely that running exploratory trial runs to establish the sensitivity of
the IBM to detect values of s around the anticipated value, could lead to optimised IBM simulation
strategies that can significantly reduce the standard errors associated with parameter estimates.
`The main factor that reduces Ne below the census size is the differences in reproductive success of
different infections (in malaria, most plausibly due to heterogeneity in mosquito biting rate and
acquired human immunity affecting an individualâ€™s infectivity and susceptibility). Adding factors that
increase this heterogeneity will further reduce Ne and hence the ability to detect low magnitudes of
s. Consequently, the ability of IBMs to detect low values of s is not simply dependent on population
size, but on their structure and calibration; this emphasises the need to continually check sensitivity
of IBMs before drawing conclusion of magnitude of selection coefficient.

3. Discussion.

13

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

IBMs for complex disease such as malaria have an intrinsic trade-off: the more realistic and complex
the biological and clinical description of transmission and disease, the more computational power is
required to simulate populations, and the smaller the number of patients/infections that can be
tracked in a reasonable timeframe. This is not usually an issue for simulating the overall
epidemiology (although stochastic loss of the pathogen population may occur at low prevalences),
and IBMs of malaria have been successfully used to investigate a number of control measures as
described in the Introduction. However, the finite sizes of IBM do affect their ability to incorporate
genetic selection of advantageous alleles. In the specific case of malaria populations, such alleles
evolve to counter control interventions such as those encoding drug resistance, vaccine insensitivity
and RDT escape-mutations. Given the likely impact of these alleles, a strategy to incorporate such
genetic processes into IBMs is urgently required and to our knowledge this is the first attempt to
explicitly do so. We make four specific recommendations that may help other researchers
attempting to do this

Recommendation #1. Report selection coefficients and validate the values obtained from IBM against
field data.
We strongly recommend that IBMs be interrogated to obtain the selection coefficient, s, of the
advantageous allele. This is a common scale which can be used to compare results from different
IBMs and which can be used to calibrate/validate against field data which typically report selection
coefficients acting on alleles (see drug resistance examples below). Selection coefficients also affect
other genetic process as was briefly described elsewhere [27] i.e. they determine rate of
geographical migration rate, survival probability of mutations (as described above), the genetic
impact of selective sweeps and determines the frequency of resistance prior to the introduction of a
novel drug as a mutation/selection balance.
As an example of IBM validation using selection coefficients, we searched the literature for
estimates of selection coefficients associated with alleles encoding malaria drug resistance in
malaria and found these range from around 0.02 to 0.12 as in the following examples (which we do
not claim to be exhaustive). Anderson & Roper [17] reported selection coefficients of 0.05 and 0.076
for two dhfr alleles and âˆ¼0.13 for a dhps allele. Anderson [28] collated data suggesting values of s
ranging from 0.03 to 0.11 for the same mutations. Estimates from SE Asia are s~=0.11 for dhfr [29]
and s~0.08 for kelch13 [30]. Nwakanma and colleagues reported values of s as 0.15, 0.13, 0.11 and
0.11 for crt, mdr, dhfr and dhps respectively over a 25 period in Gambia; note that they assumed 2
generations per year so, for consistency with the assumption of 6 generations per year, these values
should be divided by three giving estimated in the range 0.03 to 0.05. Nsanzabana et al [27] reported
values of s=0.02 to 0.6 for 3 loci undergoing selection over a 12 year period in Papua New Guinea.
IBMs producing values in this range are re-assuring while those producing higher or lower values
may require supporting clarification about why they produce results different from field
observations.
Some authors report basic genetic outputs from the models (e.g. Watson et al [31] report the spread
of hrp2-deletions from various starting frequencies; their Figure 1) while some do not report the
dynamics of mutational spread and simply report epidemiological/clinical impact (e.g. [32]). Simple
description of genetic spread and/or clinical impact are informative but we argue strongly that the
dynamics should also be described by a selection coefficient as this allows a reader to easily
calculate spread from his/her own choice of initial frequency and is a common genetic scale on
which to compare selection processes. Selection coefficient can be extracted from previous work
14

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

using our approach. For example, Watson et al [31] show the increase in frequency of hrp2-deletion
over time in their Figure 1. The change in frequency between values of 0.25 to 0.75 appears linear
for most of their plots (in line with our results, figure 1A of this paper) and generally takes 5 years,
equivalent to 30 malaria generations, to spread from 0.25 to 0.75. Substituting these values into our
Equation 3 (i.e. p(0)=0.25, p(t)=0.75, t=30) gives a value of s=0.07 which is highly consistent
with â€˜sâ€™ observed for drug resistance, presumably because the underlying selective forces are
similar i.e. drug resistance mutations survives treatment while hrp2-deletions simply
avoid treatment. This example clearly shows how reporting â€˜sâ€™ can effectively summarise a whole
graph of data (i.e. Figure 1 of [31]) while also allowing easy comparisons between studies.

We have reported selection coefficient in units per generation, even although OpenMalaria runs in
five-day timesteps with overlapping generations. The per generation timescale is a population
genetics convention but can be easily interconverted to units per day, or perhaps more convenient,
per year (it only has to be in units per generation in this work for application of Equation 4). We do
however, strongly recommend that selection coefficients be reported even if their estimation is not
the primary objective of the study For example, Nguyen et al [32] reported how selection of
malaria drug resistance affected clinical outcomes such as treatment failure rates but did not report
underlying selection coefficients; if these could have been extracted and reported it would have
helped comparability between studies, and also demonstrated that the dynamics were consistent
with field estimates describing selection for resistance.

Recommendation #2. Use the magnitude of â€˜sâ€™ to optimize the computational approach
Any IBM of finite size will inevitably have a lower limit below which â€˜sâ€™ cannot be estimated with
precision; see Figure 5. A first step would therefore be to empirically estimate its power and avoid
trying to obtain estimates of â€˜sâ€™ below this lower limit. This is particularly relevant where extensive
explorations of parameter space are planned, as it may be inevitable that small values of â€˜sâ€™ may be
encountered and need to be avoided, or possible discounted in subsequent analysis as being
unreliable. In these circumstances it is also beneficial to optimise the computational approach as
detailed earlier i.e. decide whether it is more computationally efficient to run a smaller number of
replicates of larger IBMs, or vice versa.

Recommendation #3. Consider how best to incorporate mutations
If mutations are already present in the population before deployment, presumably in
mutation/selection balance (e.g. for malaria see Equation 2 of [13]) they can be simply incorporated
as starting frequency p(0) in Equations 2 and 3. However, if new de novo mutations are to be
incorporated into the IBM, it is best to try and make details of how mutations arise external to the
simulation and summarise their input into the IBM as simple mutation rate per inoculum. In
particular, use of Equation 5 to incorporate wait times for de novo mutation to enter the population
is far more efficient than using repeat runs of the entire IBM to achieve the same purpose.
How mutations give rise to advantageous alleles may be relatively non-contentious in some
situations. For example, deletions in hrp2 or the mutations that result in altered antigenic profiles in
vaccine-escape alleles presumably reflect relative well characterised eukaryote deletion rates and
codon mutation rate, respectively. In the example of drug resistance mutations in malaria this is
15

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

extremely unclear, Hastings [14] identifying four possible sources of i.e. already present before drug
deployment in a mutation/selection balance, selected de novo from among malaria infection at time
of treatment, selected de novo from new infections emerging from the liver, spontaneous mutations
that occur in untreated humans or in the mosquito stages that are subsequently inoculated as
resistant. The relative importance of each is unknown and may even vary between drugs (e.g.
resistance to atovaquone can be observed being selected from among malaria infections at time of
treatment in around 30% of treatments [33]). Hence it makes sense to externalise assumptions
about how resistance mutations arise from the IBMs and use the latter simply to track their
subsequent rate of spread and likely clinical impact.

Recommendation #4. Explicitly discuss how selection coefficient measured in the IBM at a given
starting frequency is relevant to spread at low frequencies
There is dilemma at the heart of bringing selection into IBMs: the desire to have low advantageous
allele frequencies to reflect the epidemiological setting at which most selection occurs (Figure 1),
and the desire to have large numbers of each type of allele to accurately estimate selection
coefficients (Figure 2).
The most significant compromise we had to make in our simulations was to assume a high frequency
(10% or 50%) of the advantageous allele when introduced into the IBM to ensure a sufficiently large
number of each allelic type i.e. advantageous and wildtype. Table 1 shows that â€˜sâ€™ may vary
depending on the underlying epidemiology so the first check we made was to examine epidemiology
outputs from OpenMalaria to confirm that epidemiology was not changing rapidly as the
advantageous allele (resistance in our case) spreads. The second check was to consider if selection
coefficient may rely on allele frequency. For example spread of drug resistance may affect intrahost
dynamics to complicate and even stabilising the dynamics of spread (previously discussed in [34]).
The dynamics of hrp2-deletions provide an excellent example of how â€˜sâ€™ may depend on frequency.
Superinfection (i.e. simultaneous infection with two or more malaria clones) is common in areas of
moderate to high transmission. Hrp2-deletion mutants co-infecting humans with wildtype will be
common at low frequencies and will presumably have reduced selective advantage because the coinfecting wildtype, hrp2-expressing parasite may present a signal sufficiently strong for diagnosis to
occur. However, as deletion frequency increases, so will the proportion of superinfections consisting
solely of hrp2-deletions and this increases their selective advantage as they will escape diagnosis. In
this case we would argue that estimates of selection coefficients obtained at higher frequencies
hrp2-deletion are only valid if superinfection does not occur i.e. there is only a single malaria clones
in each host. A suitable secondary check might be to assume a variation in MOI and work out the
probability that a hrp2-deletion is detected, and then incorporate this probability of detection into
the IBM as a second check.

Conclusions.
It is fortunate that malaria, and most bacterial and viral pathogens, are haploid i.e. contain only a
single copy of each gene. If diploids are considered (e.g. the diploid worms responsible for human
diseases such as elephantiasis, river blindness etc) or insecticide-resistance in the vectors of diseases
such as malaria, sleeping sickness, tick-borne relapsing fever, the genetics becomes much more
complicated. The dominance relationship between the wildtype and advantageous allele needs to be

16

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

considered and this means that the spread of advantageous alleles will not be linear on a logit scale
(i.e. Figure 1b)
The results presented here were obtained using one specific IBM, OpenMalaria, but the underlying
principles are universal not just to malaria, but to bringing genetic selection into IBMs of other
infections (see, for example, [35] for a description of a more general, open-source IBM applicable to
several important human diseases). The most implementation-dependent recommendation is likely
to be the specifics of how to measure selection coefficient i.e. choice of starting frequency of the
advantageous allele, how long after introduction of the advantageous allele to start regression, and
the optimal duration of the regression. This may vary both with the IBMâ€™s underlying structure and
assumptions, and also with its calibrations e.g. how rapidly transmission and epidemiology stabilise
after introduction of the advantageous allele. We suggest researchers using IBMs to track genetic
spread follow a similar suite of analysis to ourselves. Our recommendation that measurement be
delayed for one malaria generation (60 days) and to continue over the subsequent 2 years (i.e. for
20 to 24 malaria generations) appears robust in our simulations and seems intuitive sensible. The
second approach, that of incorporating mutation externally to the simulations, should be widely
transferrable across IBMs. The final methodology, to validate the IBMâ€™s ability to accurate estimate
the small selection coefficient by examining CV over replicates, is also likely to be universal across
platforms; it will be highly informative to see how different platforms perform in this respect. What
is clear is that it is highly advisable to carry out these types of checks when incorporating genetic
selection into IBMs and to report them in the subsequent publications. In particular, the
recommendations we list above will apply to all IBM simulations that incorporate genetic selection,
irrespective of the disease. We do not imply that the same quantitative decisions will apply to all
systems (e.g. our decision to track selection for 720 days starting 60 days after introduction of the
advantageous allele) but we do urge other researchers to recognise that such decisions will occur in
their simulations either implicitly or explicitly, and that they be addressed and discussed. We have
tried to provide an illustrative roadmap for making such decisions and look forward to future work in
the topic.

Acknowledgements. This work was funded by the Malaria Modelling Consortium (grant # UWSC9759
to IH).

17

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

References
1.
2.

3.
4.
5.
6.

7.
8.
9.
10.
11.

12.

13.
14.
15.
16.

17.
18.
19.
20.
21.

Smith, N.R., et al., Agent-based models of malaria transmission: a systematic review. Malaria
Journal, 2018. 17(1): p. 299.
Penny, M.A., et al., Public health impact and cost-effectiveness of the RTS, S/AS01 malaria
vaccine: a systematic comparison of predictions from four mathematical models. Lancet,
2016. 387.
Brady, O.J., et al., Role of mass drug administration in elimination of Plasmodium falciparum
malaria: a consensus modelling study. The Lancet Global Health, 2017. 5(7): p. e680-e687.
Slater, H.C., et al., Assessing the impact of next-generation rapid diagnostic tests on
Plasmodium falciparum malaria elimination strategies. Nature, 2015. 528(7580): p. S94-101.
Neafsey, D.E., et al., Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria
Vaccine. N Engl J Med, 2015. 373(21): p. 2025-2037.
Genton, B., et al., A recombinant blood-stage malaria vaccine reduces Plasmodium
falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial
in Papua New Guinea. J Infect Dis, 2002. 185(6): p. 820-7.
Plowe, C.V., Vaccine-Resistant Malaria. N Engl J Med, 2015. 373(21): p. 2082-3.
Blasco, B., D. Leroy, and D.A. Fidock, Antimalarial drug resistance: linking Plasmodium
falciparum parasite biology to the clinic. Nature Medicine, 2017. 23: p. 917.
World Health Organisation, False-negative RDT results and implications of new reports of P.
falciparum histidine-rich protein 2/3 gene deletions. 2017: Geneva.
Verma, A.K., P.K. Bharti, and A. Das, HRP-2 deletion: a hole in the ship of malaria elimination.
The Lancet Infectious Diseases, 2018. 18(8): p. 826-827.
Curtis, C.F. and L.N. Otoo, A simple model of the build-up of resistance to mixtures of antimalarial drugs. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986.
80: p. 889-892.
Dye, C. and B.G. Williams, Multigenic drug resistance among inbred malaria parasites.
Proceedings of the Royal Society of London, Series B: Biological Sciences, 1997. 264: p. 6167.
Hastings, I.M., A model for the origins and spread of drug resistant malaria. Parasitology,
1997. 115: p. 133-141.
Hastings, I.M., The origins of antimalarial drug resistance. Trends in Parasitology, 2004.
20(11): p. 512-518.
Kliman, R., B. Sheehy, and J. Schultz, Genetic Drift and Effective Population Size. Nature
Education, 2008. 1(3): p. 3.
Hastings, I.M. and M.J. Donnelly, The impact of antimalarial drug resistance mutations on
parasite fitness, and its implications for the evolution of resistance. Drug Resistance Updates,
2005. 8: p. 43-50.
Anderson, T.J.C. and C. Roper, The origins and spread of antimalarial drug resistance:
Lessons for policy makers. Acta Tropica, 2005. 94(3): p. 269-280.
Hastings, I.M., Modelling parasite drug resistance: lessons for management and control
strategies. Tropical Medicine and International Health, 2001. 6(november): p. 883-890.
Hastings, I.M. and W.M. Watkins, Tolerance is the key to understanding antimalarial drug
resistance. Trends in Parasitology, 2006. 22: p. 71-77.
Hastings, I.M., How artemisinin-containing combination therapies slow the spread of
antimalarial drug resistance. Trends in Parasitology, 2011. 27: p. 67-72.
Haldane, J.B.S., A Mathematical Theory of Natural and Artificial Selection, Part V: Selection
and Mutation. Mathematical Proceedings of the Cambridge Philosophical Society, 1927.
23(7): p. 838-844.
18

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

22.
23.
24.
25.

26.

27.

28.
29.
30.
31.
32.
33.

34.
35.
36.

Charlesworth, B. and D. Charlesworth, Elements of evolutionary genetics. 2010, Colorado,
USA: Roberts and company.
Crow, J.F. and M. Kimura, An Introduction to Population Genetics Theory. 1970, New York:
Harper & Row.
Parsons, T.L., et al., Pathogen evolution in finite populations: slow and steady spreads the
best. Journal of The Royal Society Interface, 2018. 15(147).
Smith, T., et al., Relationship between the entomologic inoculation rate and the force of
infection for Plasmodium falciparum malaria. The American Journal of Tropical Medicine and
Hygiene, 2006. 75(2_suppl): p. 11-18.
Waples, R.S. and C. Do, Linkage disequilibrium estimates of contemporary Ne using highly
variable genetic markers: a largely untapped resource for applied conservation and
evolution. Evol Appl, 2010. 3(3): p. 244-62.
Nsanzabana, C., et al., Quantifying the evolution and impact of antimalarial drug resistance:
drug use, spread of resistance and drug failure over a 12 year period in Papua New Guinea. .
Journal Of Infectious Diseases, 2010. 201: p. 435-443.
Tim, J.C.A., Mapping Drug Resistance Genes in Plasmodium Falciparum by Genomewide
Association. Current Drug Targets - Infectious Disorders, 2004. 4(1): p. 65-78.
Nair, S., et al., A selective sweep driven by pyrimethamine treatment in SE Asian malaria
parasites. Molecular Biology and Evolution, 2003. 20: p. 1526-1536.
Anderson, T.J.C., et al., Population Parameters Underlying an Ongoing Soft Sweep in
Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2016. 34(1): p. 131-144.
Watson, O.J., et al., Modelling the drivers of the spread of Plasmodium falciparum hrp2 gene
deletions in sub-Saharan Africa. eLife, 2017. 6: p. e25008.
Nguyen, T.D., et al., Optimum population-level use of artemisinin combination therapies: a
modelling study. The Lancet Global Health, 2015. 3(12): p. e758-e766.
Looareesuwan, S., et al., Clinical studies of atovaquone, alone or in combination with other
antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. American
Journal of Tropical Medicine and Hygiene, 1996. 54(1): p. 62-66.
Hastings, I.M., Complex dynamics and stability of resistance to antimalarial drugs.
Parasitology, 2006. 132(Pt 5): p. 615-624.
Bershteyn, A., et al., Implementation and applications of EMOD, an individual-based multidisease modeling platform. Pathogens and Disease, 2018. 76(5).
Dykhuizen, D. and D. Hartl, Evolution of competitive ability in Escherichia coli. Evolution,
1981. 35: p. 581.

19

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

Table 1. How increasing the drug resistance level of the advantageous allele increases its selection
coefficient, s, and how the magnitude of s may vary according to infection epidemiology. Drug
resistance level is defined as the fold increase in IC50 to the antimalarial drug piperaquine compared
to the wildtype allele. Malaria treatment and epidemiology is as described as in the main text and
the simulations track 100,000 humans. The left column reports selection coefficients obtained when
malaria prevalence was 15%, while the right column reports selection coefficients obtained when
prevalence was 1.5%; all estimates started from an advantageous allele frequency of 10%.

Drug resistance level Selection coefficient (+/- s.e.).
15% prevalence
x1.0125
0.002 Â± 0.0005
x1.025
0.004 Â± 0.0004
x1.05
0.008 Â± 0.0004
x1.1
0.016 Â±0.0004
x1.2
0.030 Â±0.0004
x1.4
0.056 Â±0.0004
x2.4
0.13 Â± 0.0004

20

Selection coefficient (+/- s.e.).
1.5% prevalence
0.0001 Â± 0.002
-0.0004 Â± 0.002
0.002 Â± 0.002
0.004 Â± 0.002
0.004 Â± 0.002
0.005 Â± 0.002
0.017 Â± 0.001

bioRxiv preprint doi: https://doi.org/10.1101/819367; this version posted October 30, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-ND 4.0 International license.

Figure 1. The spread of an advantageous allele in haploid organisms such as bacteria [36] or malaria
[17]; this example illustrates dynamics for a selective advantage of s=0.07. Panel (A) shows spread
on an arithmetic scale starting from a frequency of 0.0001. Much of the timescale occurs at
frequencies that are essentially undetectable (and may be called the period of complacency) before
becoming detectable in surveys of a reasonable size. Panel (B) show the same data plotted as its
logit, ln[p/(1-p)], where p is the frequency of the advantageous allele and (1-p) is the frequency of
the wildtype allele.
(A)

Frequency of the advantageous allele (i.e. p)
0.8
0.7

Frequency

0.6
0.5
0.4
0.3
0.2
0.1
0
0

5

10

15

Time (years)

20

25

20

25

(B)

Logit of p i.e. ln[p/(1-p)]
4

ln[p(1-p)]

2
0
-2

0

5

10

15

-4
-6
-8
-10

Time (years)

21

Figure 2. How starting advantageous allele frequency (AAF) affects estimation of selection coefficient, s. The boxplots each summarise 96 to 100 estimates
except for AFF of 1% where there were 49 estimates (all runs were based on 100 simulations but the advantageous allele fell outside boundaries before
regression could be performed for some runs; see SI for more details). Selection coefficients were obtained by simulating 10,000 humans with malaria
prevalence of 15% using a regression window that starts 60 days after introduction of the advantageous allele and lasts the next 720 days (assuming AAF
stay within bounds, details in main text). Panel (A): the advantageous allele encodes a 1.1-fold increase in drug resistance (sâ‰ˆ0.02). Panel (B): the
advantageous allele encodes a 1.4-fold increase in drug resistance (sâ‰ˆ0.06). Panel(C): the advantageous allele encodes a 2.4-fold increase in drug resistance
(sâ‰ˆ0.13).

22

Figure 3. How choice of day (i.e. after introduction of the advantageous allele) used to start the regression window affects estimation of selection
coefficients. The X axis shows time post-introduction that the regression window started for values of 15, 30, 60, 120, 180, 240, 360, 540, 720, 1080, 1800
days. The boxplots each summarise 98 to 100 estimates of selection coefficient except where state otherwise*. Estimates were obtained by simulating
10,000 humans with malaria prevalence of 15% using a regression window with duration of 720 days. Left column: the advantageous allele encodes a drug
resistance increase of 1.1 fold. (sâ‰ˆ0.02). Central column: the advantageous allele encodes a drug resistance increase of 1.4 fold (sâ‰ˆ0.06). Right column: the
advantageous allele encodes a drug resistance increase of 2.4 fold (sâ‰ˆ0.13). Top row is starting advantageous allele frequency (AAF) of 10% and the lower
row is starting AAF of 50%. Bottom right panel has two anomalous results: the penultimate column has larger variation because at AAF of 50% and sâ‰ˆ0.13
then our boundary condition of AAF>90% resistance is often exceeded during the 720-day regression window so regression is performed over much
shorter periods; the last column is empty because all runs had exceeded the AAF>90% boundary at the time the window started so no regressions could be
performed.
*Under certain conditions, the boundary conditions were reached before regression could start which reduced the number of runs available for analysis.
When starting from 10% AFF with a start time of 1080 the 2.4-fold estimate was based on 84 replicates. When starting from 50% AFF with a start time of
1080 the 2.4-fold estimate was based on 50 replicates. When starting from 50% AFF with a start time of 1800 the 1.4-fold estimate was based on 92
replicates and there were no results for the 2.4-fold increase.

23

Figure 3.

.

24

Figure 4. How duration of regression window affects estimation of selection coefficients. The X axis gives duration of regression window and values of 120,
240, 360, 720, 1080, 1880 and 2880 days were investigated. The boxplots each summarise 98 to 100 estimates of selection coefficient obtained from a
simulation of 10,000 humans with malaria prevalence of 15% using a regression window that starts 60 days after introduction of the advantageous allele;
Left column: the advantageous allele encodes a drug resistance increase of 1.1 fold (sâ‰ˆ0.018). Central column: the advantageous allele encodes a drug
resistance increase of 1.4 fold (sâ‰ˆ0.058). Right column: the advantageous allele encodes a drug resistance increase of 2.4 fold (sâ‰ˆ0.13). Top row is starting
advantageous allele frequency (AAF) of 10% and the lower row is starting AAF of 50%.

25

Figure 5: How the power of a simulation to detect small selection coefficients depends on its size. Four parametrisations were investigated
â€¢
â€¢
â€¢
â€¢

The default simulation size i.e. 10,000 humans with a malaria prevalence of 15%; starting advantageous allele frequency (AAF) of 10%
The default simulation size used in this work i.e. 10,000 humans with a malaria prevalence of 15%; starting AAF of 50%
Simulation of 100,000 humans with a starting AAF of 50% and malaria prevalence of 1.5%, meaning malaria population size is nearly identical (there
will be stochastic differences) to the 2nd parameterisation where population size is 10,000 but prevalence is 15%.
Simulation of 100,000 humans with a starting AAF of 50% and malaria prevalence of 15% i.e. a 10 fold increase in malaria population size compared
to the default size of 10,000

Each parameterisation was run 100 times and selection coefficient estimated by regressing over 720 days starting 60 days after introduction of the
advantageous allele. Note that the third parameterisation (red line) is associated with lower selection coefficients (see Table 1) and consequently is only
plotted at the extreme left of the X axis.

26

